(lp0
S"BioDelivery Sciences International, Inc.  Files An 8-K Other Events Market Exclusive - 17 hours ago BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using&nbsp;...BioDelivery Sciences International's  CEO Dr. Mark Sirgo on Q4 2016 ... - Seeking AlphaBioDelivery Q4 Loss Wider Than Expected; Revenues in Line March 17, 2017 - Zacks.com"
p1
aS'BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth ... PR Newswire  - Mar 9, 2017 RALEIGH, N.C., March 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc.  announced that it will report its fourth quarter and full-year 2016 financial results and host a conference call and webcast at 8:00 AM Eastern Time on&nbsp;...FY2017 EPS Estimates for BioDelivery Sciences International, Inc. (BDSI ... - Sports PerspectivesBioDelivery Sciences International Inc. - Receive News &amp; Ratings Daily - BBNS'
p2
aS'BRIEF-BioDelivery Sciences Q4 loss per share $0.29 Reuters - Mar 17, 2017 Biodelivery sciences international inc - expect approval of belbuca in canada in first half of 2017. * Biodelivery sciences international inc- had cash and cash equivalents of approximately $32.0 million at december 31, 2016. Source text for Eikon ...'
p3
aS'BioDelivery Sciences Announces the Hiring of Peter Ginsberg as Vice President ... PR Newswire  - Dec 14, 2016 RALEIGH, N.C., Dec. 14, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc.  announced that Peter Ginsberg has joined the company as Vice President of Business Development.Company Update : Why BioDelivery Sciences International, Inc ... - Smarter AnalystOn heels of Belbuca reacquisition, BDSI makes business development hire - Triangle Business Journal'
p4
aS'BioDelivery Sciences Reacquires License to BELBUCA from Endo Pharmaceuticals PR Newswire  - Dec 8, 2016 RALEIGH, N.C., Dec. 8, 2016 /PRNewswire/ --BioDelivery Sciences International, Inc.  announced that it has entered into an agreement with Endo Pharmaceuticals, Inc.  terminating their licensing of rights for BELBUCA&nbsp;...BioDelivery Regains Belbuca Opioid Rights  - InvestopediaEndo Sells Back Rights for Opioid Painkiller - Wall Street Journal'
p5
aS'MonoSol Rx Files Patent Infringement Suit against BioDelivery Sciences ... GlobeNewswire  - Jan 13, 2017 ... a specialty pharmaceutical company utilizing its PharmFilm drug delivery technology to improve patient outcomes and to address unmet needs, today filed a patent infringement case against BioDelivery Sciences International, Inc. (Nasdaq:BDSI ...'
p6
aS'BioDelivery Sciences International, Inc.  Shares Open Higher on Back of ... Smarter Analyst - Sep 23, 2016 BioDelivery Sciences International, Inc.  shares are up 13% this morning, after Janney Montgomery analyst Ken Trbovich upgraded BDSI from a Neutral to a Buy rating with a price target of $4, which implies an upside of 63% from current&nbsp;...Janney Montgomery Scott Upgrades BioDelivery Sciences International  to Buy - StreetInsider.com'
p7
aS"Can BioDelivery Succeed With Belbuca? Seeking Alpha - Feb 10, 2017 BioDelivery  gave a pretty good presentation about Belbuca and the company's sales and marketing strategy going forward."
p8
aS'BioDelivery Sciences to Present at the 29th Annual ROTH Conference Yahoo Finance - Mar 8, 2017 RALEIGH, N.C., March 8, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc.  announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference. The presentation, which will be&nbsp;...Biodelivery Sciences International Inc  Files Form 4 Insider Selling ... - Energy IndexStock to Watch: BioDelivery Sciences International, Inc.  - Is stories'
p9
aS"BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a ... PR Newswire  - May 11, 2016 RALEIGH, N.C., May 11, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc.  and Collegium Pharmaceutical, Inc.  today announced the signing of a licensing agreement under which BDSI is granting the exclusive&nbsp;...Biodelivery Shareholders Should Be Disappointed With Collegium Deal - Seeking AlphaSluggish painkiller sales still hurting Raleigh's BioDelivery Sciences - Triangle Business Journal"
p10
a.